Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Innovation Council · Running

IOO - Improving IO IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.

Coordinator
Fastbase Solutions Sociedad Limitada, Spain
Runs
1 August 2024 to 31 December 2026
Status
Running
EU funding
€2.5m
Total cost
€3.6m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
101161495

What the project is doing

In the project's own words, from its summary on CORDIS.

Immunotherapy is a beacon of hope in cancer's battle, but with a 10-20% response rate in solid tumors, its potential is untapped. Predicting patient responses to treatment, which current methods are ill-equipped for, is an urgent unmet medical need. Our project stands for industrializing our analytically validated multiplexed protein-function based biomarker assay (IOO), currently TRL6, which is based on our proprietary bio-imaging technology.

Whilst scientifically validated, we need further clinical validation to obtain increased datasets required for regulatory certification for clinical deployment. This assay could triple the efficacy of currently available immune-oncology treatments by accurately predicting patient response to immune checkpoint inhibitors - the basis of 90% of current immuno-oncology therapies. If successful, we will bring this transformative solution to hospitals worldwide.

The upshot could be game-changing: doubling survival rates for high-prevalence, lethal tumors like lung cancer.

Topics

Who is involved

OrganisationCityCountryRole
Fastbase Solutions Sociedad LimitadaDerio BizkaiaSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI